The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
出版年份 2016 全文链接
标题
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
作者
关键词
-
出版物
PLoS One
Volume 11, Issue 1, Pages e0146337
出版商
Public Library of Science (PLoS)
发表日期
2016-01-06
DOI
10.1371/journal.pone.0146337
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats
- (2015) Yuka Hayashizaki-Someya et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
- (2014) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
- (2013) Jason R. Clapper et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Obesity-Associated Nonalcoholic Fatty Liver Disease
- (2013) Yusuf Yilmaz et al. Clinics in Liver Disease
- Obesity and Liver Disease
- (2013) Kathleen E. Corey et al. Clinics in Liver Disease
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
- (2013) Melania Gaggini et al. Nutrients
- Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
- (2012) Masakazu Imamura et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Mechanisms for Insulin Resistance: Common Threads and Missing Links
- (2012) Varman T. Samuel et al. CELL
- Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
- (2012) G. Musso et al. DIABETOLOGIA
- Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
- (2012) Kenneth Cusi GASTROENTEROLOGY
- Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
- (2012) Vivian A. Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice
- (2012) Atsuo Tahara et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Why Does NAFLD Predict Type 2 Diabetes?
- (2011) Guido Lattuada et al. Current Diabetes Reports
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- (2011) Atsuo Tahara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
- (2010) L. Zhang et al. DIABETES OBESITY & METABOLISM
- Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
- (2010) P. Ferré et al. DIABETES OBESITY & METABOLISM
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histopathology of Non-Alcoholic Fatty Liver Disease
- (2009) Elizabeth M. Brunt Clinics in Liver Disease
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
- (2009) Kittichai Promrat et al. HEPATOLOGY
- Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis
- (2009) Koji Fujita et al. HEPATOLOGY
- Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent
- (2008) Laura H. Tetri et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet
- (2008) Mary E. Rinella et al. JOURNAL OF LIPID RESEARCH
- Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
- (2008) N. Anderson et al. PHARMACOLOGICAL REVIEWS
- Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
- (2008) Harmeet Malhi et al. SEMINARS IN LIVER DISEASE
- Insulin resistance, inflammation, and non-alcoholic fatty liver disease
- (2008) Herbert Tilg et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now